🔬 Four important discussions from the final Presidential Sessions at #ESMO26!

💊 KEYNOTE-C93: Pembrolizumab monotherapy improved PFS in dMMR advanced or recurrent endometrial cancer, although the prespecified non-inferiority criterion was not met. An important step toward chemotherapy-free treatment.

🎯 Sacituzumab tirumotecan (sac-TMT): Impressive results in previously treated endometrial cancer, with improved PFS (7.2 vs 3.9 months) and OS (19.0 vs 12.1 months). ADCs are clearly changing the landscape!

🧬 MOIO trial: Can we safely extend immunotherapy intervals to every 3 months? The trial stopped early, leaving the question statistically unresolved and highlighting the challenges of treatment de-escalation.

📊 Non-inferiority: Who decides how much efficacy we can afford to lose? A great reminder that statistical margins must also reflect clinical judgment and patient preferences.

Four discussions that could shape how we design trials and treat patients in the coming years. 💚

@osutcuoglu @uyargalip @kbaskurtt
@tubaugurdr @drOrhunakdogan
@myESMO

#ESMO26 #ESMO2026 #Oncology #Immunotherapy #EndometrialCancer #ADC #ClinicalTrials